New Enzyme Shows Promise in Reversing Aging Effects on Human Tissue
A groundbreaking study from Revel Pharmaceuticals in San Francisco has introduced a synthetic enzyme that may reverse some effects of aging in human tissue by targeting advanced glycation end products (AGEs). These compounds, which accumulate in the body over time, have long been associated with various age-related health issues, including heart disease and diabetes. Traditionally, the damage caused by AGEs was thought to be irreversible, but this new research offers a glimmer of hope.
The study's authors designed an enzyme that specifically targets the most prevalent type of AGE found in human tissues. In their experiments, they applied this enzyme to aortic tissue from a 75-year-old donor, achieving a remarkable reduction in AGE levels to those comparable to a 30-year-old. This significant finding suggests that it may be possible to repair some of the damage caused by aging at the molecular level.
AGEs, often referred to as the body's rust, accumulate in structural proteins and contribute to the stiffening of tissues, leading to various health complications. The research team, led by Revel CEO Aaron Cravens, emphasized that their work challenges the long-held belief that such molecular damage is permanent. "This work establishes that damage to aging proteins previously thought to be irreversible can be repaired," Cravens stated.
The enzyme they developed, known as CMLase, was engineered from a microbial source and underwent extensive testing to enhance its efficiency. Initial laboratory tests demonstrated that CMLase could effectively cleave CML molecules, a particularly stubborn type of AGE, from various proteins, restoring their original structures.
While the enzyme has shown promise in vitro, the next steps involve determining its efficacy in living organisms. The researchers opted to test CMLase on human tissue slices rather than animal models, which may not accurately reflect the long-term accumulation of AGEs. The results from these tests were encouraging, revealing a roughly 70 percent reduction in CML levels in the aortic tissue samples.
Despite the encouraging results, the researchers caution that chemical reversal of AGE damage does not automatically equate to rejuvenation of tissue. The long-term implications of removing AGEs from tissues remain uncertain, and further research is needed to explore how this could affect overall tissue health and function.
The potential applications of CMLase are vast, ranging from treatments for skin aging to therapies for organ rejuvenation. However, challenges remain, including safety concerns regarding the enzyme's origin from bacteria, which could provoke immune responses in the human body. Additionally, the enzyme's stability and ability to penetrate biological barriers present further hurdles that need to be addressed.
Overall, this research opens new avenues for understanding and potentially treating the effects of aging at a molecular level, suggesting that engineered enzymes like CMLase could play a crucial role in future therapeutic strategies against age-related decline.




